Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
about
Emerging utility of once-weekly exenatide in patients with type 2 diabetesAdverse Effects of GLP-1 Receptor AgonistsTreatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitorsLipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear?Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Cardiovascular safety profile of currently available diabetic drugs.Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients.Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 DiabetesA genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.Combination therapy when metformin is not an option for type 2 diabetes.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Albiglutide: a unique GLP-1 receptor agonist.Exenatide once weekly improved 24-hour glucose control and reduced glycemic variability in metformin-treated patients with type 2 diabetes: a randomized, placebo-controlled trial.Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.Persistent injection site nodules from exenatide: Successful treatment with intralesional triamcinolone
P2860
Q26777320-3F5FE880-ABA8-4D0A-8594-8ADEA6B5B24EQ26801346-787D970F-520A-4771-B535-5F5BBE9ED85FQ27021870-C5AD4268-50D5-4F2B-9EDE-43147EE46516Q28072729-7FD3B983-E9C6-4007-8A5C-4A74E61B6E74Q31066859-77FFD00C-238F-4A49-B513-943333EF7448Q34971736-5F27C22B-EF54-4E8E-933F-9844E6EAFFEFQ35654002-7AD5436C-C4F9-450E-83CB-8D7CB0DA29A6Q35918380-60F4026F-BEE7-409B-BED0-DC726E1E9184Q37568754-D1F32F03-3580-45FE-9DB2-B9A3A344939DQ37639310-0C6E91FD-0D2A-4565-9C2E-67211B7315CEQ38377267-68BF9F13-7824-4B44-B1EC-FA2DC8E3A5D9Q38526870-3B082DF8-A1A6-4A69-A75A-BF40025698E2Q38602769-44480C3F-A1B3-42E5-B5D6-6F8648348A6CQ38966029-DF1328D4-67A2-46A4-837F-C9EA41ECB9CCQ40574678-7A9E3668-80C8-4FBC-B315-600CA5DA8ADCQ47386231-0DAE6DE8-6AF4-493A-935B-DC42C5C0C505Q48228283-1DF9AD8C-273E-4DD2-B555-EA64B9D10796Q51699823-58F6D173-8F6D-47B8-8FDE-5A21A2803AE0Q58726028-2984D45D-B1BC-454F-9121-48FFC409D6B2
P2860
Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Efficacy, safety, and tolerabi ...... alysis of the DURATION trials.
@en
type
label
Efficacy, safety, and tolerabi ...... alysis of the DURATION trials.
@en
prefLabel
Efficacy, safety, and tolerabi ...... alysis of the DURATION trials.
@en
P2093
P2860
P356
P1476
Efficacy, safety, and tolerabi ...... nalysis of the DURATION trials
@en
P2093
Christine T Schulteis
Haiying Dong
Jaret Malloy
Michael Grimm
Pete Griffin
P2860
P356
10.3810/PGM.2013.05.2660
P50
P577
2013-05-01T00:00:00Z